<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046223</url>
  </required_header>
  <id_info>
    <org_study_id>202011092RINA</org_study_id>
    <nct_id>NCT05046223</nct_id>
  </id_info>
  <brief_title>Comparison of iGel and THRIVE on Bronchoscopic Interventions</brief_title>
  <official_title>Analysis of Intraoperative Homeostasis and Postoperative Recovery After Interventional Bronchoscopy With Different Anesthetic Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      THRIVE and iGEL were applied for maintain oxygenation in bronchoscopic interventions which&#xD;
      could not performed with an endotracheal tube. However, besides the risk of desaturation, the&#xD;
      differences on difficulties to approach vocal cords, the responses to spay of local&#xD;
      anesthetics including cough or spasm, the CO2 elimination, the hemodynamic changes, and the&#xD;
      effects on postoperative recovery are rarely investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      THRIVE and iGEL were applied for maintain oxygenation in bronchoscopic interventions which&#xD;
      could not performed with an endotracheal tube. Unlike the nasal cannula with THRIVE, the tips&#xD;
      of iGel are located in upper esophagi, it may affect the postoperative swallowing, especially&#xD;
      for the aged group. However, the bronchoscopic approach may be easier for an established&#xD;
      route to vocal cords. With shared airway for ventilation and interventions, CO2 elimination&#xD;
      is hardly monitored besides the risk of desaturation.&#xD;
&#xD;
      In this study, THRIVE or iGel was planned to be randomized used for bronchoscopic&#xD;
      interventions in an adult group (age 20-65) and an aged group (age over 65). The difficulties&#xD;
      to approach vocal cords, the responses to spay of local anesthetics including cough or spasm,&#xD;
      the CO2 elimination, the hemodynamic changes, and the effects on postoperative recovery are&#xD;
      compared between THRIVE and iGel groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difficulty of bronchoscopic approach</measure>
    <time_frame>from bronchoscopic insertion to visualize vocal cords</time_frame>
    <description>time from insertion to visualize vocal cord, records of manipulations if applied</description>
  </primary_outcome>
  <primary_outcome>
    <measure>response to spraying local anesthetics by bronchoscopy</measure>
    <time_frame>from visualizng vocal cords to complete local anesthetic spray in trachea and main bronchi</time_frame>
    <description>the status of vocal cords visualized (relaxed, closed, relaxed but close with spray of local anesthetics); cough scale during bronchoscopic insertion and spray of local anesthetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemodynamic changes</measure>
    <time_frame>from bronchoscopic insertion to 20 minutes after completion of local anesthetic spraying</time_frame>
    <description>changes on MAP (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cough scale</measure>
    <time_frame>from bronchoscopic insertion to the end of procedure</time_frame>
    <description>cough intensity X times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPO2</measure>
    <time_frame>every 5 minutes from bronchoscopic insertion to the end of procedure</time_frame>
    <description>pulse oximeter, hemoglobin saturation (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transdermal CO2</measure>
    <time_frame>every 5 minutes from bronchoscopic insertion to the end of procedure</time_frame>
    <description>data obyenied from transdermal CO2 (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postanesthetic recovery</measure>
    <time_frame>from admission to PACU to discharge from PACU</time_frame>
    <description>time stay in postoperative care unit (minutes)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>perioperative swallowing function</measure>
    <time_frame>preoperative and postoperative day 1</time_frame>
    <description>EAT-10 questionnaire (score)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lung Diseases</condition>
  <condition>Total Intravenous Anesthesia</condition>
  <condition>Tracheal Diseases</condition>
  <arm_group>
    <arm_group_label>high-flow nasal oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THRIVE( Transnasal humidified rapid-insufflation ventilatory exchange), a method of high-flow nasal oxygen (HFNO), is planned to applied for bronchoscopic interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supraglottic devise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iGel, a supraglottic devise with tip in upper esophagus, is planned to applied for bronchoscopic interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.</intervention_name>
    <description>cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions</description>
    <arm_group_label>high-flow nasal oxygen</arm_group_label>
    <arm_group_label>supraglottic devise</arm_group_label>
    <other_name>hemodynamic and ventilatory responses from insertion of broncoscopy to the end of bronchoscopic interventions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>postoperative recovery</intervention_name>
    <description>anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1</description>
    <arm_group_label>high-flow nasal oxygen</arm_group_label>
    <arm_group_label>supraglottic devise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  plan to receive bronchoscopic interventions with total intravenous anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  awake bronchoscopy pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Chang Tsai</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yajung Cheng</last_name>
    <phone>0223123456</phone>
    <phone_ext>65517</phone_ext>
    <email>chengyj@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Cancer Center</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yajung cheng, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Tracheal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>if there is similar investigation</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year after completion of investigation</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

